Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Endologix, Inc.
A new global clinical trial initiative is assessing a number of second-generation candidate vaccines for COVID-19. The Australian medicines regulator has given the go-ahead for an approval application for one of the vaccines, from Taiwan’s Medigen.
The US agency’s Circulatory System Devices Panel found type III endoleaks are still a problem for abdominal aortic aneurysm patients treated with the newest Endologix stent graft, though for some the benefits still outweigh the risks. The panel advised that all patients, however, should continue getting annual screenings.
Advisory committees within the US agency will hold an October session on a PMA for Integra’s SurgiMend PRS ABDM, as well as a two-day session on endovascular graft safety in November.
Seattle biotech raised $36m series A in March, now obtains glaucoma and AMD drug candidates along with delivery technology. Alligator, Orion partner on bispecific antibodies for cancer.
- Medical Devices
- Implantable Devices
- Infusion Therapy Equipment and Supplies
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- Cardiovascular Dynamics, Inc.
- Nellix, Inc.
- PQ Bypass, Inc.
- Radiance Medical Systems, Inc.